Algeta

Top 10 Pharma M&A deals of 2013
Top 10 Pharma M&A deals of 2013
Fierce Pharma
M&A
Amgen
ONYX Pharmaceuticals
Bausch & Lomb
Valeant Pharmaceuticals
Elan
Perrigo
Actavis
Warner Chilcott
Bristol-Myers Squibb
AstraZeneca
Pearl Therapeutics
Agila
Mylan
Salix
Santarus
Bayer
Algeta
Shire
ViroPharma
Flag link:
Bayer says takeover offer for Algeta successful
Bayer says takeover offer for Algeta successful
Reuters
Bayer
Algeta
M&A
Flag link:
Bayer Set to Acquire Algeta in First Quarter
Bayer Set to Acquire Algeta in First Quarter
Marketwatch
Bayer
Algeta
M&A
Flag link:
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs
Fierce Biotech
JPMHC 2014
Algeta
Macrogenics
Xencor
Acetylon
Enanta Pharmaceuticals
Clinigen
Iroko Pharmaceuticals
Protalix BioTherapeutics
Ambrx
Roche
Sialix
Verastem
pRED
Cubist Pharmaceuticals
Celgene
Otonomy
Lumena Pharmaceuticals
Flag link:
Bayer wins Norway cancer firm Algeta with raised $2.9 billion offer
Bayer wins Norway cancer firm Algeta with raised $2.9 billion offer
Reuters
Algeta
Bayer
M&A
Flag link:
Bayer bids $2.4 billion for Norwegian cancer drug partner Algeta
Bayer bids $2.4 billion for Norwegian cancer drug partner Algeta
Yahoo/Reuters
Bayer
M&A
Algeta
Flag link:
Norway's Algeta says prostate cancer drug makes solid U.S. debut
Norway's Algeta says prostate cancer drug makes solid U.S. debut
Reuters
Algeta
prostate cancer
Xofigo
Flag link:
Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug
Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug
Bloomberg
Bayer
Algeta
FDA
prostate cancer
Xofigo
Flag link:
Algeta Sees ’Widespread’ Interest in Thorium Cancer Technology
Algeta Sees ’Widespread’ Interest in Thorium Cancer Technology
Bloomberg
Algeta
Thorium-227
cancer
Flag link:
Blockbuster buzz: 15 top therapies in late-stage development
Blockbuster buzz: 15 top therapies in late-stage development
Fierce Biotech
vortioxetine
Vectura
tofacitinib
Takeda
T-DM1
Sanofi
Roche
REGN727
Regeneron
Reata
QVA149
Pfizer
Odanacatib
Novartis
MorphoSys
Merck
macitentan
Lundbeck
Immunogen
GSK
GS-7977
Gilead
gantenerumab
Eliquis
darapladib
Bristol-Myers Squibb
Biogen Idec
BG-12
Bayer
Bardoxolone
Anacetrapib
Alpharadin
Algeta
Actelion
AbbVie
Flag link:
Bayer Drug Hailed As Prostate Cancer Game Changer
Bayer Drug Hailed As Prostate Cancer Game Changer
TheStreet.com
Bayer
prostate cancer
Algeta
Amgen
Xgeva
Exelixis
Alpharadin
Flag link:
First Phase III trial of an alpha-pharmaceutical
First Phase III trial of an alpha-pharmaceutical
eurekalert.org
Bone metastases
prostate cancer
Alpharadin
Algeta
Bayer
Flag link:
Algeta shares spike on promising prostate cancer drug data
Algeta shares spike on promising prostate cancer drug data
Fierce Biotech
Algeta
prostate cancer
Apharadin
Flag link:
Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New Orleans
Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New Orleans
Medical News Today
Algeta
prostate cancer
Flag link:
Bayer to Pay Up to $800 Million for Algeta’s New Drug
Bayer to Pay Up to $800 Million for Algeta’s New Drug
Bloomberg
Bayer
Algeta
Alpharadin
prostate cancer
Flag link: